Document:

EX-10.1

 Exhibit 10.1 
  

 
 June 5, 2013 
 Eliseo
Salinas, M.D. 
 XXXXX 
 XXXXX 

Dear Eliseo, 
 On behalf of StemCells, Inc., I am pleased to
offer you the position of Executive Vice President and Head of Research and Development on the following terms and conditions: 
  

	 	(1)	Job Responsibilities. Unless otherwise agreed in writing, your first day of employment will be June 6, 2013. You will report directly to me and work at our offices located at 7707 Gateway Blvd in Newark,
California. Initially your duties and responsibilities will include, but will not be limited to: (1) leading a world-class neuroscience research and development organization at the Company, (2) expanding the Company’s CNS clinical
research efforts to include new clinical trials in multiple disease indications, and (3) developing the Company’s programs and portfolios to help attract new business opportunities. 

 

	 	(2)	Consulting Agreement. Your consulting agreement with the Company, dated October 2, 2012, will be terminated as of your first day of employment, without any further payments or obligations being owed
thereunder. 

  

	 	(3)	Salary. Beginning on your first day of employment, your base salary will be at the rate of $475,000 per year, paid bi-weekly, every other Friday. In addition, you will be eligible for a bonus of up to 50% of your
annual base salary (calculated as of January 1 of the year for which bonuses are awarded). Funding of the bonus program is at the discretion of the Company’s Board of Directors and is based upon their evaluation of the Company’s
performance versus previously determined goals for the year. You will be eligible for inclusion in the Bonus Plan for the 2013 fiscal year, based upon your performance consistent with Company practices. 

In addition, starting in July 2013, the Company will provide you with a sign-on bonus of $100,000, to be paid quarterly in four equal
payments of $25,000 each. 
  

	 	(4)	Restricted Stock Units. You will be granted three hundred ninety thousand (390,000) Restricted Stock Units (“RSUs”), pursuant to the Company’s 2012 Commencement Incentive Plan (the “2012
Plan”). This RSU grant will vest over four years, with 1/4 vesting on each of the first four anniversaries of your employment. Upon hire, you will receive an “Equity Award Agreement” under the 2012 Plan to confirm the terms and

  
  

 

			
	USA	 	Europe
	7707 Gateway Blvd	 	Minerva Building 250, Babraham Research Campus
	Newark, CA 94560 USA	 	Cambridge CB22 3AT United Kingdom
	T  +1  (510)  456-4000    —    F  +1  (510)  456-4001	 	T  +44  (0)  1223
499160    —    F  +44  (0)  1223  499178

www.stemcellsinc.com 

	 	
conditions of these grants, including the fact that grants under the 2012 Plan are subject in their entirety to the provisions of the 2006 Equity Plan such as continued employment to receive
vested shares. A copy of the Prospectus for the 2006 Equity Plan will be provided to you when your employment begins. All grants under the “2012 Plan” are subject to shareholder notification through a press release. 

	 	(5)	Benefits. As an employee of StemCells, you will be eligible to participate in a comprehensive benefits program which currently includes: medical, dental and vision benefits for you and your dependents; term life
insurance equivalent to two times your annual base salary up to $800,000; short and long-term disability insurance; and a 401(k) savings plan and employer match, which is currently made in Company stock. You will be eligible to participate in these
plans on the first of the month following your start date, except that you may elect to participate in the 401(k) plan immediately. Details of these benefit plans will be provided to you upon your employment. Your paid time off (PTO) as a full-time
employee will be 25 days (200 hours) per year, accrued at a rate of 7.69 hours per pay period, up to the maximum accrual permitted by Company policy. In addition, the Company currently offers eight paid holidays per year. 

 

	 	(6)	Relocation. The Company will provide you with a relocation allowance of $50,000 to help in the transition of your primary residence from Pennsylvania to California, provided you complete your relocation within 12
months of your date of hire. After you have completed your relocation, you may submit receipts or other evidence of the relocation to request the allowance. The allowance will be subject to applicable withholding taxes, although you may recover some
of these taxes by deducting the moving expenses from your federal income taxes. You agree to repay the $50,000 relocation allowance to the Company if you voluntarily terminate your position within 12 months of your receipt of the allowance.

  

	 	(7)	Employment Documentation; Fitness to Work. As a condition of employment with StemCells, you will be required to: (1) sign and return both a copy of this letter and a copy of the enclosed Employment
Agreement, which prohibits among other things the unauthorized use or disclosure of Company proprietary information and requires the assignment of intellectual property (IP) rights to any invention made by you as part of your work at StemCells; and
(2) on or before the first day of your employment, provide documents from the enclosed List of Acceptable Documents which prove your identity and right to work in the United States. You will also be expected to (i) abide by Company rules
and regulations, (ii) sign and comply with the Company’s Code of Ethics and Conduct, Harassment Policy and Publication Policy, and (iii) acknowledge in writing that you will read and comply with the Company’s Employee Handbook.
You also must sign and return at least one week before your first day of employment the enclosed employment application and release authorization for a background check. This offer is contingent on satisfactory completion of reference checking by
the Company. 

 You have an option to receive the Hepatitis B vaccine which is paid for by the Company. A form to elect or
decline the vaccine is enclosed. Please fill out the form, sign and return it to Human Resources. 

	 	(8)	Confidentiality. As a Company employee, you will be expected not to use or disclose any confidential information, including trade secrets, of any former or current employer or any other person to whom you have an
obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally
in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises any unpublished documents or property belonging to any former or current employer or other person to whom you
have an obligation of confidentiality. During our discussions about your proposed job duties, you assured us that you would be able to perform your responsibilities within the guidelines just described. 

 

	 	(9)	At-Will Employment; Termination and Termination Benefits. As set forth in your Employment Agreement, your employment with StemCells will be on an at-will basis and for an unspecified duration, which means that
neither this Letter Agreement nor any policy or procedure of StemCells (including the stock vesting and other payments made to you by the Company over time based on your continued employment with the Company), nor any verbal representation, shall
confer any right to continuing employment. Either you or StemCells may terminate your employment relationship at any time with or without cause. In addition, the Company expressly reserves the right to modify your compensation and benefits from time
to time as it deems necessary or advisable. In the event of termination of your employment, you will not be entitled to any severance pay or other benefits, damages or compensation of any kind, except as provided in this Letter Agreement.

 If your employment with StemCells is involuntarily terminated without cause at any time, you will be provided with salary
continuation and benefits continuation under COBRA from the date of termination until the date twelve (12) months after the effective date of termination equal to the salary which you were receiving at the time of such termination; payments
shall be paid in accordance with the Company’s standard payroll practices upon the Company’s receipt of a signed general release of any claims, whether known or unknown, against the Company and its agents. 

In the event of a Company change of control and either (i) your employment is involuntarily terminated, or (ii) you voluntarily
terminate your employment because your job responsibilities have been materially and adversely impacted as a result of the change of control, you will be provided with salary continuation and benefits continuation under COBRA from the date of
termination until the date twelve (12) months after the effective date of termination equal to the salary which you were receiving at the time of such termination; payments shall be paid in accordance with the Company’s standard payroll
practices upon the Company’s receipt of a signed general release of any claims, whether known or unknown, against the Company and its agents. 

If your employment is terminated for cause or you choose to resign without good cause, you will not be entitled to any severance payments or
other benefits. 
 This letter, which includes your Employment Agreement, supersedes all prior discussions, agreements and writings with regard to your
employment and any related matters. The 

 
terms of this conditional offer can only be amended in a written document signed by you and an officer of the Company. Also, final terms of your employment must be approved by the Company’s
Compensation Committee. 
 Please indicate your acceptance of the terms and conditions of this conditional employment offer by signing this letter and the
enclosed Employment Agreement and returning them both to me. 
 On behalf of the entire Company, I am delighted at the prospect of your joining us as Head
of Research and Development, as we work together to deliver the promise of this exciting technology to physicians and patients, while at the same time creating value for our employees and shareholders alike. We truly believe that you will greatly
contribute to the success of StemCells, and we all look forward to working with you. 
 Sincerely, 

/s/ Martin McGlynn 
 Martin McGlynn 

President and CEO 
  

	Enclosures:	Employment Agreement 

	  	List of Acceptable Documents 

	  	Form to elect or decline Hepatitis B vaccine 

	  	Code of Ethics and Conduct 

	  	Release Authorization 

	  	Employment Application 

 I accept the foregoing conditional offer of employment on the terms and conditions
outlined above. 
  

			
	 /s/ Eliseo Salinas, M.D.
	  	 5 June 2013

	Eliseo Salinas, M.D.	  	DateEX-10.1

 Exhibit 10.1 

MODIFICATION AGREEMENT 

This MODIFICATION AGREEMENT (this “Agreement”) is entered into as of October 30, 2013, between Guidance Software, Inc.,
a Delaware corporation, with an address of 1055 E. Colorado Blvd., Pasadena, CA 91106 (the “Borrower”) and Bank of the West, a California banking corporation with an address of 2527 Camino Ramon, San Ramon CA 94583 (the
“Lender”). 
 WHEREAS, the Lender has made a loan to the Borrower (the “Loan”); 

WHEREAS, The Loan is evidenced by that certain Line of Credit Note, Dated July 12, 2012 (as previously amended, modified or supplemented,
the “Note”), by the Borrower in favor of the Lender which matures June 30, 2014 (the “Expiration Date”); 

WHEREAS, in connection with the Loan, Guidance Software, Inc. entered into 1) that certain Loan and Security Agreement, dated July 12,
2012 (as previously amended, modified or supplemented, the “Guidance Software, Inc. Loan Agreement”), in favor of the Lender; 

WHEREAS, pursuant to the Guidance Software, Inc. Loan Agreement, Guidance Software, Inc. granted the Lender a first priority security interest
in and lien on the personal property described therein (the “Guidance Software Personalty”); 
 WHEREAS, the Guidance Software,
Inc. Loan Agreement, and the Line of Credit Note and all other documents and instruments executed in connection with or relating to the Loan are referred to herein, collectively, as the “Loan Documents”; and the Guidance Software, Inc.
Personalty and all other collateral granted to the Lender to secure the Loan is referred to herein, collectively, as the “Collateral”; 

WHEREAS, the Borrower has requested and the Lender has agreed to amend certain of the covenants applicable to the Loan; 

WHEREAS, the Borrower and the Lender have agreed to modify the Loan and the Loan Documents in accordance with the terms of this Agreement.

 NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Lender and the
Borrower mutually agree as follows: 
 1. MODIFICATION AGREEMENT 

1.1. Recitals and Representations Accurate. The above recitals are hereby made a part of this Agreement and the Borrower acknowledges and agrees that
each of the recitals is true and correct. 
 1.2. Ratification. All of the terms, covenants, provisions, representations, warranties, and conditions
of the Loan Documents, as amended or modified hereby, are ratified, acknowledged, confirmed, and continued in full force and effect as if fully restated herein. 

1.3. Collateral. The Borrower confirms and ratifies its continuing mortgage, pledge, assignment, and/or grant of security interest in and lien on the
Collateral to and in favor of the Lender as set forth in the Loan Documents. 

  
 

 

 1.4. Modification of Material Notices: Section 4.13 of the Loan Agreement is deleted in its entirety
and the following is substituted in lieu thereof: 
 Borrower shall give the Lender prompt written notice of any and all (i) litigation,
arbitration or administrative proceedings to which Borrower is a party and in which the claim or liability exceeds $500,000.00 or which affects the Collateral; (ii) other matters which have resulted in, or might result in a material adverse
change in the Collateral or the financial condition or business operations of Borrower, and (iii) any enforcement, cleanup, removal or other governmental or regulatory actions instituted, completed or threatened against Borrower or any of its
properties. 
 1.5. Modification of Definitions and/or Financial Covenants: Section 4.15(b) of the Loan Agreement is deleted in its entirety and
the following is substituted in lieu thereof: 
 Minimum Cash and Securities. Borrower shall maintain unrestricted cash, and
Marketable Securities in an amount of not less than $15,000,000.00, as measured at each fiscal quarter end, for the period commencing July 1, 2013 through June 30, 2014, and $12,500,000.00 thereafter. 

1.6. Modification of Definitions and/or Financial Covenants: Section 4.15(e) of the Loan Agreement is deleted in its entirety and the following is
substituted in lieu thereof: 
 Year to Date Losses. Borrower shall not allow Year to Date Loss to exceed $11,800,000.00 for the
quarter ending September 30, 2013, $13,200,000.00 for the quarter ending December 31, 2013 and $5,000,000.00 for the quarter ending March 31, 2014, and each quarter thereafter. For the purposes of this section, “Year to Date
Loss” shall mean Net Income after taxes plus stock compensation expense plus non-cash charges related to amortization of intangibles, measured for the fiscal year to date. 

1.7. Modification of Loans and Advances: Section 4.18 of the Loan Agreement is deleted in its entirety. 

1.8. Modification of Investments: Section 4.19 of the Loan Agreement is deleted in its entirety. 

1.9. Modification of Judgment Default: Section 5.1(k) of the Loan Agreement is deleted in its entirety and the following is substituted in lieu
thereof: 
 A final, non-appealable judgment or judgments for the payment of money shall be rendered against the Borrower or any guarantor of
the Obligation, and any such judgment shall remain unsatisfied and in effect for any period of thirty (30) consecutive days without a stay of execution except for judgments issued in the ordinary course of business not to exceed $500,000.00
in any fiscal year. 
 1.10. Representations and Warranties. The Borrower hereby represents and warrants to the Lender that: 

 

	 	(a)	The person executing this Loan Agreement is duly authorized to do so and to bind the Borrower to the terms hereof; 

  

	 	(b)	Each of the Loan Documents is a valid and legal binding obligation of the Borrower, enforceable in accordance with its terms, and is not subject to any defenses, counterclaims, or offsets of any kind; 

 

	 	(c)	All financial statements delivered to the Lender were true, accurate and complete, in all material respects, as of the date of delivery to the Lender; 

 

	 	(d)	Since the date of the Loan Documents there has been no material adverse change in the condition, financial or otherwise, of the Borrower, except as disclosed to the Lender in writing; 

  
 

 

	 	(e)	There exists no action, suit, proceeding or investigation, at law or in equity, before any court, board, administrative body or other entity, pending or threatened, affecting the Borrower or its property, wherein an
unfavorable decision, ruling or finding would materially adversely affect the business operations, property or financial condition of the Borrower; and 

  

	 	(f)	Except as disclosed to the Lender, there exists no event of default, or other circumstance that with the passage of time or giving of notice or both will become an event of default, under any of the Loan Documents.

 1.11. Interest, Fees, Costs and Expenses. The Borrower shall, simultaneously with the execution of this Agreement, pay to the Lender
all accrued interest owing on the Loan as of the date of this Agreement together with all fees, costs and expenses due and owing to the Lender by the Borrower under the Loan Documents. 

2. MISCELLANEOUS 
 2.1. Release of the
Lender. The Borrower hereby confirms that as of the date hereof it has no claim, set-off, counterclaim, defense, or other cause of action against the Lender including, but not limited to, a defense of usury, any claim or cause of action at
common law, in equity, statutory or otherwise, in contract or in tort, for fraud, malfeasance, misrepresentation, financial loss, usury, deceptive trade practice, or any other loss, damage or liability of any kind, including, without limitation, any
claim to exemplary or punitive damages arising out of any transaction between the Borrower and the Lender. To the extent that any such set-off, counterclaim, defense, or other cause of action may exist or might hereafter arise based on facts known
or unknown that exist as of this date, such set-off, counterclaim, defense and other cause of action is hereby expressly and knowingly waived and released by the Borrower. The Borrower acknowledges that this release is part of the consideration to
the Lender for the financial and other accommodations granted by the Lender in this Agreement. 
 2.2. Costs and Expenses. The Borrower shall pay to
the Lender on demand any and all costs and expenses (including, without limitation, reasonable attorneys’ fees and disbursements, court costs, litigation and other expenses) incurred or paid by the Lender in establishing, maintaining,
protecting or enforcing any of the Lender’s rights or any of the obligations owing by the Borrower to the Lender, including, without limitation, any and all such costs and expenses incurred or paid by the Lender in defending the Lender’s
security interest in, title or right to, the Collateral or in collecting or attempting to collect or enforcing or attempting to enforce payment of the Loan. 

2.3. Indemnification. The Borrower shall indemnify, defend and hold the Lender and its directors, officers, employees, agents and attorneys (each an
“Indemnitee”) harmless against any claim brought or threatened against any Indemnitee by the Borrower or any guarantor or endorser of the obligations of the Borrower to the Lender, or any other person (as well as from attorneys’ fees
and expenses in connection therewith) on account of the Lender’s relationship with the Borrower, or any guarantor or endorser of the obligations of the Borrower to the Lender (each of which may be defended, compromised, settled or pursued by
the Lender with counsel of the Lender’s election, but at the expense of the Borrower), except for any claim arising out of the gross negligence or willful misconduct of the Lender. The within indemnification shall survive payment of the
obligations of the Borrower to the Lender, and/or any termination, release or discharge executed by the Lender in favor of the Borrower. 
 2.4.
Severability. If any provision of this Agreement or portion of such provision or the application thereof to any person or circumstance shall to any extent be held invalid or unenforceable, the remainder of this Agreement (or the remainder of
such provision) and the application thereof to other persons or circumstances shall not be affected thereby. 
 2.5. Counterparts. This Agreement may
be executed in two or more counterparts, each of which shall be an original, but all of which shall constitute but one agreement. 

  
 

 

 2.6. Complete Agreement. This Agreement and the other Loan Documents constitute the entire agreement and
understanding between and among the parties hereto relating to the subject matter hereof, and supersedes all prior proposals, negotiations, agreements and understandings among the parties hereto with respect to such subject matter. 

2.7. Binding Effect of Agreement. This Agreement shall be binding upon and inure to the benefit of the respective heirs, executors, administrators,
legal representatives, successors and assigns of the parties hereto, and shall remain in full force and effect (and the Lender shall be entitled to rely thereon) until released in writing by the Lender. The Lender may transfer and assign this
Agreement and deliver the Collateral to the assignee, who shall thereupon have all of the rights of the Lender; and the Lender shall then be relieved and discharged of any responsibility or liability with respect to this Agreement and the
Collateral. Except as expressly provided herein or in the other Loan Documents, nothing, expressed or implied, is intended to confer upon any party, other than the parties hereto, any rights, remedies, obligations or liabilities under or by reason
of this Agreement or the other Loan Documents. 
 2.8. Further Assurances. The Borrower will from time to time execute and deliver to the Lender such
documents, and take or cause to be taken, all such other further action, as the Lender may request in order to effect and confirm or vest more securely in the Lender all rights contemplated by this Agreement (including, without limitation, to
correct clerical errors) or to vest more fully in or assure to the Lender the security interest in the Collateral or to comply with applicable statute or law and to facilitate the collection of the Collateral (including, without limitation, the
execution of stock transfer orders and stock powers, endorsement of promissory notes and instruments and notifications to obligors on the Collateral). To the extent permitted by applicable law, the Borrower authorizes the Lender to file financing
statements, continuation statements or amendments without the Borrower’s signature appearing thereon, and any such financing statements, continuation statements or amendments may be signed by the Lender on behalf of the Borrower, if necessary,
and may be filed at any time in any jurisdiction. The Lender may at any time and from time to time file financing statements, continuation statements and amendments thereto which contain any information required by the Uniform Commercial Code of
California as amended from time to time (the “Code”) for the sufficiency or filing office acceptance of any financing statement, continuation statement or amendment, including whether the Borrower is an organization, the type of
organization and any organization identification number issued to the Borrower. The Borrower agrees to furnish any such information to the Lender promptly upon request. In addition, the Borrower shall at any time and from time to time take such
steps as the Lender may reasonably request for the Lender (i) to obtain an acknowledgment, in form and substance satisfactory to the Lender, of any bailee having possession of any of the Collateral that the bailee holds such Collateral for the
Lender, (ii) to obtain “control” (as defined in the Code) of any Collateral comprised of deposit accounts, electronic chattel paper, letter of credit rights or investment property, with any agreements establishing control to be in
form and substance satisfactory to Lender, and (iii) otherwise to insure the continued perfection and priority of the Lender’s security interest in any of the Collateral and the preservation of its rights therein. The Borrower hereby
constitutes the Lender its attorney-in-fact to execute, if necessary, and file all filings required or so requested for the foregoing purposes, all acts of such attorney being hereby ratified and confirmed; and such power, being coupled with an
interest, shall be irrevocable until this Agreement terminates in accordance with its terms, all obligations of the Borrower to the Lender are irrevocably paid in full and the Collateral is released. 

2.9. Amendments and Waivers. This Agreement may be amended and the Borrower may take any action herein prohibited, or omit to perform any act herein
required to be performed by it, if the Borrower shall obtain the Lender’s prior written consent to each such amendment, action or omission to act. No delay or omission on the part of the Lender in exercising any right hereunder shall operate as
a waiver of such right or any other right and waiver on any one or more occasions shall not be construed as a bar to or waiver of any right or remedy of the Lender on any future occasion. 

  
 

 

 2.10. Terms of Agreement. This Agreement shall continue in force and effect so long as any obligation of
the Borrower to Lender shall be outstanding and is supplementary to each and every other agreement between the Borrower and Lender and shall not be so construed as to limit or otherwise derogate from any of the rights or remedies of Lender or any of
the liabilities, obligations or undertakings of the Borrower under any such agreement, nor shall any contemporaneous or subsequent agreement between the Borrower and the Lender be construed to limit or otherwise derogate from any of the rights or
remedies of Lender or any of the liabilities, obligations or undertakings of the Borrower hereunder, unless such other agreement specifically refers to this Agreement and expressly so provides. 

2.11. Notices. Any notices under or pursuant to this Agreement shall be deemed duly received and effective if delivered in hand to any officer or agent
of the Borrower or Lender, or if mailed by registered or certified mail, return receipt requested, addressed to the Borrower or Lender at the address set forth in the Credit Agreement or as any party may from time to time designate by written notice
to the other party. 
 2.12. California Law. This Agreement shall be governed by federal law applicable to the Lender and, to the extent not preempted
by federal law, the laws of the State of California without giving effect to the conflicts of laws principles thereof. 
 2.13. Reproductions. This
Agreement and all documents which have been or may be hereinafter furnished by Borrower to the Lender may be reproduced by the Lender by any photographic, photostatic, microfilm, xerographic or similar process, and any such reproduction shall be
admissible in evidence as the original itself in any judicial or administrative proceeding (whether or not the original is in existence and whether or not such reproduction was made in the regular course of business). 

2.14. Venue. Borrower irrevocably submits to the nonexclusive jurisdiction of any Federal or state court sitting in California, over any suit, action or
proceeding arising out of or relating to this Agreement. Borrower irrevocably waives to the fullest extent it may effectively do so under applicable law, any objection it may now or hereafter have to the laying of the venue of any such suit, action
or proceeding brought in any such court and any claim that the same has been brought in an inconvenient forum. Borrower irrevocably appoints the Secretary of State of the State of California as its authorized agent to accept and acknowledge on its
behalf any and all process which may be served in any such suit, action or proceeding, consents to such process being served (i) by mailing a copy thereof by registered or certified mail, postage prepaid, return receipt requested, to
Borrower’s address shown above or as notified to the Lender and (ii) by serving the same upon such agent, and agrees that such service shall in every respect be deemed effective service upon Borrower. 

2.15. Waiver Of Jury Trial. THE BORROWER AND LENDER ACKNOWLEDGE THAT THE RIGHT TO TRIAL BY JURY IS A CONSTITUTIONAL RIGHT, AND THAT IT MAY BE WAIVED
UNDER CERTAIN CIRCUMSTANCES. TO THE EXTENT PERMITTED BY LAW EACH PARTY, AFTER CONSULTING (OR HAVING THE OPPORTUNITY TO CONSULT) WITH COUNSEL OF ITS CHOICE, WAIVES ANY RIGHT TO TRIAL BY JURY IN THE EVENT OF LITIGATION RELATED TO THIS CREDIT AGREEMENT
OR ANY OTHER DOCUMENT, INSTRUMENT OR TRANSACTION BETWEEN THE PARTIES. 
 2.16. Judicial Reference Provision. In the event the above Jury Trial Waiver
is unenforceable, the parties elect to proceed under this Judicial Reference Provision. With the exception of the items specified below, any controversy, dispute or claim between the parties relating to this Credit Agreement or any other document,
instrument or transaction between the parties (each, a “Claim”), will be resolved by a reference proceeding in California pursuant to Sections 638 et seq. of the California Code of Civil Procedure, or their successor sections, which shall
constitute the exclusive remedy for the resolution of any Claim, including whether the Claim is subject to reference. Venue for the reference will be the Superior Court in the County where real property involved in the action, if any, is located, or
in a County where venue is otherwise appropriate under law (the “Court”). The following matters shall not be subject to reference: (i) nonjudicial foreclosure of any security interests in real or personal property, (ii) exercise
of self-help remedies (including without limitation set-off), (iii) appointment of a receiver, and (iv) temporary, provisional or ancillary remedies (including without limitation writs of attachment, writs of possession, temporary
restraining orders or preliminary injunctions). The exercise of, or opposition to, any of the above does not waive the right to a reference hereunder. 

  
 

 

 The referee shall be selected by agreement of the parties. If the parties do not agree, upon
request of any party a referee shall be selected by the Presiding Judge of the Court. The referee shall determine all issues in accordance with existing case law and statutory law of the State of California, including without limitation the rules of
evidence applicable to proceedings at law. The referee is empowered to enter equitable and legal relief, and rule on any motion which would be authorized in a court proceeding, including without limitation motions for summary judgment or summary
adjudication. The referee shall issue a decision, and pursuant to CCP §644 the referee’s decision shall be entered by the Court as a judgment or order in the same manner as if tried by the Court. The final judgment or order from any
decision or order entered by the referee shall be fully appealable as provided by law. The parties reserve the right to findings of fact, conclusions of law, a written statement of decision, and the right to move for a new trial or a different
judgment, which new trial if granted, will be a reference hereunder. AFTER CONSULTING (OR HAVING THE OPPORTUNITY TO CONSULT) WITH COUNSEL OF ITS CHOICE, EACH PARTY AGREES THAT ALL CLAIMS RESOLVED UNDER THIS REFERENCE PROVISION WILL BE DECIDED BY A
REFEREE AND NOT A JURY. 
  

					
	Executed as of the date written above.
		
		 	Borrower:
		
		 	Guidance Software, Inc.
		 	a Delaware corporation
			
		 	By:	 	/s Barry Plaga
		 		 	Barry Plaga, Chief Financial Officer

  

			
	Accepted: Bank of the West
		
	By:	 	/s/ Nabil Khoury
		 	Nabil Khoury, Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]